vs

Side-by-side financial comparison of NEKTAR THERAPEUTICS (NKTR) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

PEDEVCO CORP is the larger business by last-quarter revenue ($23.1M vs $21.8M, roughly 1.1× NEKTAR THERAPEUTICS). PEDEVCO CORP runs the higher net margin — -36.8% vs -165.4%, a 128.6% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs -25.3%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 0.4%).

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

NKTR vs PED — Head-to-Head

Bigger by revenue
PED
PED
1.1× larger
PED
$23.1M
$21.8M
NKTR
Growing faster (revenue YoY)
PED
PED
+143.5% gap
PED
118.2%
-25.3%
NKTR
Higher net margin
PED
PED
128.6% more per $
PED
-36.8%
-165.4%
NKTR
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NKTR
NKTR
PED
PED
Revenue
$21.8M
$23.1M
Net Profit
$-36.1M
$-8.5M
Gross Margin
Operating Margin
-126.9%
-21.3%
Net Margin
-165.4%
-36.8%
Revenue YoY
-25.3%
118.2%
Net Profit YoY
-596.9%
-243.5%
EPS (diluted)
$-4.67
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NKTR
NKTR
PED
PED
Q4 25
$21.8M
$23.1M
Q3 25
$11.8M
$7.0M
Q2 25
$11.2M
$7.0M
Q1 25
$10.5M
$8.7M
Q4 24
$29.2M
$10.6M
Q3 24
$24.1M
$9.1M
Q2 24
$23.5M
$11.8M
Q1 24
$21.6M
$8.1M
Net Profit
NKTR
NKTR
PED
PED
Q4 25
$-36.1M
$-8.5M
Q3 25
$-35.5M
$-325.0K
Q2 25
$-41.6M
$-1.7M
Q1 25
$-50.9M
$140.0K
Q4 24
$7.3M
$5.9M
Q3 24
$-37.1M
$2.9M
Q2 24
$-52.4M
$2.7M
Q1 24
$-36.8M
$773.0K
Gross Margin
NKTR
NKTR
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
NKTR
NKTR
PED
PED
Q4 25
-126.9%
-21.3%
Q3 25
-268.6%
-12.0%
Q2 25
-324.2%
-32.2%
Q1 25
-425.8%
1.7%
Q4 24
49.2%
-12.9%
Q3 24
-142.4%
31.3%
Q2 24
-211.9%
22.3%
Q1 24
-163.7%
7.6%
Net Margin
NKTR
NKTR
PED
PED
Q4 25
-165.4%
-36.8%
Q3 25
-301.3%
-4.7%
Q2 25
-372.2%
-24.0%
Q1 25
-486.4%
1.6%
Q4 24
24.9%
56.0%
Q3 24
-153.6%
32.2%
Q2 24
-222.9%
22.7%
Q1 24
-170.1%
9.5%
EPS (diluted)
NKTR
NKTR
PED
PED
Q4 25
$-4.67
$-2.23
Q3 25
$-1.87
$0.00
Q2 25
$-2.95
$-0.02
Q1 25
$-0.24
$0.00
Q4 24
$-2.07
$2.69
Q3 24
$-2.66
$0.03
Q2 24
$-3.76
$0.03
Q1 24
$-0.19
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NKTR
NKTR
PED
PED
Cash + ST InvestmentsLiquidity on hand
$15.1M
$3.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$89.8M
$207.4M
Total Assets
$280.4M
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NKTR
NKTR
PED
PED
Q4 25
$15.1M
$3.2M
Q3 25
$41.0M
$10.9M
Q2 25
$43.0M
$8.5M
Q1 25
$38.9M
$10.4M
Q4 24
$44.3M
$4.0M
Q3 24
$30.1M
$4.6M
Q2 24
$27.9M
$6.1M
Q1 24
$48.6M
$13.3M
Stockholders' Equity
NKTR
NKTR
PED
PED
Q4 25
$89.8M
$207.4M
Q3 25
$85.1M
$115.4M
Q2 25
$-24.2M
$115.2M
Q1 25
$13.7M
$116.2M
Q4 24
$60.7M
$115.6M
Q3 24
$48.9M
$106.5M
Q2 24
$79.7M
$103.2M
Q1 24
$126.7M
$100.0M
Total Assets
NKTR
NKTR
PED
PED
Q4 25
$280.4M
$375.9M
Q3 25
$301.3M
$135.9M
Q2 25
$207.5M
$136.8M
Q1 25
$256.2M
$145.6M
Q4 24
$303.9M
$128.3M
Q3 24
$308.0M
$114.3M
Q2 24
$343.3M
$111.0M
Q1 24
$396.0M
$118.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NKTR
NKTR
PED
PED
Operating Cash FlowLast quarter
$-65.0M
$-2.1M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NKTR
NKTR
PED
PED
Q4 25
$-65.0M
$-2.1M
Q3 25
$-48.8M
$7.4M
Q2 25
$-45.7M
$-420.0K
Q1 25
$-49.1M
$5.9M
Q4 24
$-46.2M
$4.2M
Q3 24
$-43.9M
$8.3M
Q2 24
$-37.7M
$4.6M
Q1 24
$-47.9M
$-4.3M
Free Cash Flow
NKTR
NKTR
PED
PED
Q4 25
$-65.0M
Q3 25
$-48.9M
Q2 25
$-45.8M
Q1 25
$-49.1M
Q4 24
$-46.6M
Q3 24
$-44.6M
Q2 24
$-37.9M
Q1 24
$-48.0M
FCF Margin
NKTR
NKTR
PED
PED
Q4 25
-298.0%
Q3 25
-414.5%
Q2 25
-409.6%
Q1 25
-469.0%
Q4 24
-159.9%
Q3 24
-184.9%
Q2 24
-161.3%
Q1 24
-222.0%
Capex Intensity
NKTR
NKTR
PED
PED
Q4 25
0.1%
Q3 25
1.0%
Q2 25
0.3%
Q1 25
0.0%
Q4 24
1.6%
Q3 24
2.8%
Q2 24
0.8%
Q1 24
0.7%
Cash Conversion
NKTR
NKTR
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
-6.36×
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons